EGFR and neoplasm: In FGFR1high and FGF2high NCI-H1650 and HCC1569 xenograft tumors, co-treatment with FGFR-TKIs and EGFR-TKI osimertinib or HER2-TKI neratinib strongly inhibited tumor growth and ERK phosphorylation compared with osimertinib or neratinib alone, whereas FGFR1low and FGF2low II-18 xenograft tumors did not affect tumor growth (Fig. 5c and Supplementary Fig. 7E, –G).